Collective Management of Intellectual Property Rights
Medicines Patent Pool agreement with Gilead contains flexibilities including termination provisions and severability of licenses
Submitted by Krista Cox on 25. July 2011 - 13:38On 12 July 2011, the Medicines Patent Pool (MPP) and Gilead announced an agreement for Gilead to license patents for tenofovir (TDF), emtricitabine (FTC), elvitegravir (EVG), cobisistat (COBI) and a four drug combination of these drugs. KEI's initial comments on the agreement are available here.
KEI comment on the Medicines Patent Pool license with Gilead
Submitted by James Love on 11. July 2011 - 18:17KEI comment on the Medicines Patent Pool license with Gilead
July 12, 2011
FYI: James Love (Tuesday: +44.785.543.6510, james.love@keionline.org). Thiru Balasubramaniam (thiru@keionline.org) or Krista Cox (krista.cox@keionline.org, +1.202.332.2670).
USPTO statement at WIPO side event on Medicines Patent Pool
Submitted by James Love on 18. May 2011 - 8:25This is the statement that was delivered by Karin L. Ferriter (from USPTO and USTR), at a UNITAID side event on the Medicines Patent Pool, during a break of the WIPO Standing Committee on the Law of Patents.
Statement on Medicines Patent Pool Side Event
Civil Society comments on USPTO humanitarian priority review voucher proposal
Submitted by Judit Rius on 22. November 2010 - 10:53On November 19, 2010, Knowledge Ecology International, Medecins Sans Frontieres/Doctors without Borders, Oxfam America and Public Citizen answered a Request for Comments from the US Department of Commerce on a proposal to "Incentivize Humanitarian Technologies and Licensing Through the Intellectual Property System".
Global Fund calls upon drug companies to "share without delay" AIDS drug patents with the Medicines Patent Pool
Submitted by Judit Rius on 5. November 2010 - 9:44In a October 7, 2010 letter, Professor Michel Kazatchkine, the Executive Director of the Global Fund to fight AIDS, Tuberculosis and Malaria, has written to Dr. Jorge Bermudez, the UNITAID Executive Director, to discuss the Medicines Patent Pool.
Kazatchkine congratulates UNITAID for the announcement that an agreement had been reached between U.S. National Institute for Health and the Medicines Patent Pool for the voluntary license of the NIH patents rights on an HIV-AID drug, Darunavir.
KEI Statement on UNITAID Decision to Approve Creation of a Patent Pool for AIDS medicines
Submitted by James Love on 15. December 2009 - 1:22On Monday, December 14, the UNITAID board passed a resolution to establish a Patent Pool for AIDS medicines. The decision caped a dramatic debate on the proposal, which had been before UNITAID since 2006, and had been discussed in other fora since 2002. The following is a statement by KEI on the UNITAID decision, followed by background on the UNITAID patent pool proposal, including a copy of the UNITAID press release.
Statement of James Love, Director of KEI, on the UNITAID Patent Pool:
Survey of Patent Pools Demonstrates Variety of Purposes and Management Structures
Tuesday, 05 June 2007
Table of Contents
An pdf version of this document is available here.
KEI Research Note 2007:6
David Serafino[1]
Knowledge Ecology International
4 June 2007
David Serafino[1]
Knowledge Ecology International
4 June 2007
Table of Contents
EMILA Working Plan
Saturday, 02 June 2007
The Essential Medical Inventions Licensing Agency
Working Plan, June 1, 2007
Introduction
IGWG Briefing Paper on Patent Pools
Sunday, 03 June 2007
IGWG Briefing Paper on Patent Pools
Collective Management of Intellectual Property -- The use of Patent Pools to expand access to essential medical technologies
KEI Research Note 2007:3 (1)
UNITAID Patent Pool for Medicines
In 2007 Medécins sans Frontières (MSF, Doctors Without Borders) and Knowledge Ecology International (KEI) presented a proposal for UNITAID to host a medicines patent pool.
In July 2008 the UNITAID Board supported the principle of establishing a patent pool for medicines to provide patients in low and middle income countries with increased access to more appropriate and lower price medicines.
